The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Benefit of perioperative chemotherapy in the patients with loco-regional recurrence of HR-positive HER2-negative breast cancer: A multi-institutional retrospective cohort study.
 
Yukinori Ozaki
Honoraria - Chugai Pharma; Daiichi Sankyo; Kyowa Kirin International; Lilly; Pfizer
 
Emi Tokuda
Speakers' Bureau - AstraZeneca; Chugai Pharma; MSD K.K; Pfizer; Taiho Pharmaceutical
 
Fumikata Hara
Honoraria - Chugai Pharma; Daiichi Sankyo; Kyowa Kirin; Lilly Japan; MSD; Pfizer; Taiho Pharmaceutical
 
Shinsuke Sasada
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Gilead Sciences (Inst); Lilly Japan (Inst); Nipro Corporation (Inst)
 
Yasuaki Sagara
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Japan; Eisai; Lilly; MSD; Pfizer
 
Masataka Sawaki
No Relationships to Disclose
 
Chizuko Kanbayashi
No Relationships to Disclose
 
Takashi Yamanaka
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Kyowa Kirin International; Lilly Japan; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Daiichi Sankyo/UCB Japan; Lilly Japan
 
Tatsuya Onishi
Honoraria - AstraZeneca; Daiichi Sankyo; Medtronic
 
Yoshitaka Fujiki
No Relationships to Disclose
 
Akihiko Suto
No Relationships to Disclose
 
Yuko Takahashi
Research Funding - MSD
 
Eriko Tokunaga
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/UCB Japan; Lilly Japan
 
Tomoyuki Aruga
Speakers' Bureau - AstraZeneca; Chugai Pharma; Kyowa Kirin International; Lilly; Pfizerr
Research Funding - Pfizer
 
Rikiya Nakamura
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Kyowa Kirin International; Lilly Japan; MSD Oncology; Nihonkayaku; Nihonkayaku; Novartis
 
Tomomi Fujisawa
Speakers' Bureau - AstraZeneca; AstraZeneca; Daiichi Sankyo; Kyowa Kirin International; Lilly
 
Shigehira Saji
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Exact Sciences; Kyowa Kirin; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Daiichi Sankyo/UCB Japan; Kyowa Kirin; MSD; Roche/Genentech
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; MSD; Novartis; Pfizer; Sanofi
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
 
Tadahiko Shien
Consulting or Advisory Role - Allergan; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
Speakers' Bureau - Allergan; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly; Nihonkayaku; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Eisai (Inst); Nihonkayaku (Inst)